Literature DB >> 21165652

Abnormal expression and dysfunction of novel SGLT2 mutations identified in familial renal glucosuria patients.

Lei Yu1, Ji-Cheng Lv, Xu-jie Zhou, Li Zhu, Ping Hou, Hong Zhang.   

Abstract

Familial renal glucosuria (FRG) is characterized by persistent glucosuria despite normal serum glucose and in the absence of overt tubular dysfunction. Mutation of sodium/glucose co-transporter 2 (SGLT2) has been identified and was recently reported to be involved in FRG. However, the functional and pathological consequences of such mutations remain unknown. In the current study, we collected four families with FRG. Sequencing of the SGLT2 coding region, intronic segments and cDNA revealed three missense mutations (294C>A: F98L; 1388T>G: L463R; 1435C>G: R479G) and two splice mutations (IVS 1-16 C>A: Del exon3; IVS 11+1 G>C: Del exon11). The probands were either heterozygous or compound heterozygous for SGLT2 mutations, and had glucosuria quantified at 6-27 g/day. Human 293 cells were transfected with the plasmid constructs to study the expression and function of SGLT2 mutants in vitro. Confocal microscopy using green fluorescent protein (GFP) revealed that the mutation results in a loss of punctate membrane pattern typical of the wild-type SGLT2 except in the 294C>A mutant. All mutants had significantly lower transport capacity in comparison to the wild-type control (26.49-71.48%). Renal biopsy in one consenting proband revealed significantly lower SGLT2 expression in the apical side of the proximal convoluted tubule in comparison to both healthy and disease controls (minimal change disease and diabetic nephropathy). The current study provides functional clues regarding the SGLT2 molecule from genotype to phenotype in FRG families. © Springer-Verlag 2010

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21165652     DOI: 10.1007/s00439-010-0927-z

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  20 in total

1.  Long-term outcome of renal glucosuria type 0: the original patient and his natural history.

Authors:  Sabine Scholl-Bürgi; René Santer; Jochen H H Ehrich
Journal:  Nephrol Dial Transplant       Date:  2004-09       Impact factor: 5.992

2.  A novel SGLT2 mutation in a patient with autosomal recessive renal glucosuria.

Authors:  Jean Francis; Junhui Zhang; Anita Farhi; Hugh Carey; David S Geller
Journal:  Nephrol Dial Transplant       Date:  2004-11       Impact factor: 5.992

3.  Inhibitor binding in the human renal low- and high-affinity Na+/glucose cotransporters.

Authors:  Ana M Pajor; Kathleen M Randolph; Sandy A Kerner; Chari D Smith
Journal:  J Pharmacol Exp Ther       Date:  2007-12-06       Impact factor: 4.030

4.  Labeling the components of the plasma membrane with fluorescent dyes for imaging.

Authors:  Brad Chazotte
Journal:  CSH Protoc       Date:  2008-02-01

5.  Localization of the Na+/glucose cotransporter gene SGLT2 to human chromosome 16 close to the centromere.

Authors:  R G Wells; T K Mohandas; M A Hediger
Journal:  Genomics       Date:  1993-09       Impact factor: 5.736

6.  SGLT2 mediates glucose reabsorption in the early proximal tubule.

Authors:  Volker Vallon; Kenneth A Platt; Robyn Cunard; Jana Schroth; Jean Whaley; Scott C Thomson; Hermann Koepsell; Timo Rieg
Journal:  J Am Soc Nephrol       Date:  2010-07-08       Impact factor: 10.121

7.  Transforming growth factor beta-induced phosphorylation of Smad3 is required for growth inhibition and transcriptional induction in epithelial cells.

Authors:  X Liu; Y Sun; S N Constantinescu; E Karam; R A Weinberg; H F Lodish
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-30       Impact factor: 11.205

8.  Molecular analysis of the SGLT2 gene in patients with renal glucosuria.

Authors:  René Santer; Martina Kinner; Christoph L Lassen; Reinhard Schneppenheim; Paul Eggert; Martin Bald; Johannes Brodehl; Markus Daschner; Jochen H H Ehrich; Markus Kemper; Salvatore Li Volti; Thomas Neuhaus; Flemming Skovby; Peter G F Swift; Jürgen Schaub; Dan Klaerke
Journal:  J Am Soc Nephrol       Date:  2003-11       Impact factor: 10.121

Review 9.  The SLC2 family of facilitated hexose and polyol transporters.

Authors:  Marc Uldry; Bernard Thorens
Journal:  Pflugers Arch       Date:  2003-05-16       Impact factor: 3.657

10.  The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose.

Authors:  Y Kanai; W S Lee; G You; D Brown; M A Hediger
Journal:  J Clin Invest       Date:  1994-01       Impact factor: 14.808

View more
  19 in total

1.  Familial renal glucosuria: a clinicogenetic study of 23 additional cases.

Authors:  HyunKyung Lee; Kyoung Hee Han; Hye Won Park; Jae Il Shin; Chan Jong Kim; Mee Kyung Namgung; Kee Hyuck Kim; Ja Wook Koo; Woo Young Chung; Dae-Yeol Lee; Su-Yung Kim; Hae Il Cheong
Journal:  Pediatr Nephrol       Date:  2012-07       Impact factor: 3.714

2.  Impact of an SGLT2-loss of function mutation on renal architecture, histology, and glucose homeostasis.

Authors:  Corey B Hughes; George M Mussman; Phil Ray; Robert C Bunn; Virgilius Cornea; Kathryn M Thrailkill; John L Fowlkes; Iuliana Popescu
Journal:  Cell Tissue Res       Date:  2021-01-06       Impact factor: 5.249

3.  A novel sodium-glucose co-transporter 2 gene (SGLT2) mutation contributes to the abnormal expression of SGLT2 in renal tissues in familial renal glucosuria.

Authors:  Lei Yu; Ping Hou; Ji-Cheng Lv; Guo-Ping Liu; Hong Zhang
Journal:  Int Urol Nephrol       Date:  2014-06-08       Impact factor: 2.370

Review 4.  Renal sodium-glucose cotransporter inhibition in the management of type 2 diabetes mellitus.

Authors:  Muhammad A Abdul-Ghani; Luke Norton; Ralph A DeFronzo
Journal:  Am J Physiol Renal Physiol       Date:  2015-09-09

5.  A novel SGLT is expressed in the human kidney.

Authors:  Rajendra K Kothinti; Amy B Blodgett; Paula E North; Richard J Roman; Niloofar M Tabatabai
Journal:  Eur J Pharmacol       Date:  2012-07-03       Impact factor: 4.432

6.  High urinary glucose is associated with improved renal prognosis in patients with diabetes mellitus.

Authors:  Yuya Itano; Hiroshi Sobajima; Norimi Ohashi; Taiga Shibata; Atsushi Fujiya; Takanobu Nagata; Masahiko Ando; Takahiro Imaizumi; Yoko Kubo; Takaya Ozeki; Takayuki Katsuno; Sawako Kato; Yoshinari Yasuda; Shoichi Maruyama
Journal:  J Diabetes Investig       Date:  2020-11-16       Impact factor: 4.232

7.  SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria.

Authors:  Yukihiro Chino; Yoshishige Samukawa; Soichi Sakai; Yasuhiro Nakai; Jun-ichi Yamaguchi; Takeo Nakanishi; Ikumi Tamai
Journal:  Biopharm Drug Dispos       Date:  2014-08-06       Impact factor: 1.627

Review 8.  Patient profiling in diabetes and role of canagliflozin.

Authors:  Ambika Amblee
Journal:  Pharmgenomics Pers Med       Date:  2014-11-18

9.  Use of systems pharmacology modeling to elucidate the operating characteristics of SGLT1 and SGLT2 in renal glucose reabsorption in humans.

Authors:  Yasong Lu; Steven C Griffen; David W Boulton; Tarek A Leil
Journal:  Front Pharmacol       Date:  2014-12-10       Impact factor: 5.810

10.  Decreased expression and function of sodium-glucose co-transporter 2 from a novel C-terminal mutation: a case report.

Authors:  Lei Yu; Qiaozhi Xu; Ping Hou; Hong Zhang
Journal:  BMC Nephrol       Date:  2016-03-21       Impact factor: 2.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.